Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Dymista | Azelastine HCl and fluticasone propionate | Seasonal allergic rhinitis | Do not list | Complete | ||
| Abstral | Fentanyl citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
| Targin | Oxycodone HCI / naloxone HCI | Pain, moderate to severe and relief of opioid-induced constipation | Do not list | Complete | ||
| Byetta | Exenatide | Diabetes mellitus, type 2 | Do not list | Complete | ||
| Ozurdex | Dexamethasone intravitreal implant | Macular edema, central retinal vein occlusion | Do not list | Complete | ||
| Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
| Benlysta | Belimumab | Systemic lupus erythematosus | Do not list | Complete | ||
| Gelnique | Oxybutynin Chloride Gel | Overactive bladder | Do not list | Complete | ||
| RAPAFLO | Silodosin | Benign prostatic hyperplasia | Do not list | Complete | ||
| Saphris | Asenapine | Schizophrenia | Do not list | Complete |
Last Updated : May 17, 2024